Solid cancer: the new tumour spread endpoint opens novel opportunities

Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced ima...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Michael, Rosel, Daniel, Brábek, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889500/
https://www.ncbi.nlm.nih.gov/pubmed/31427682
http://dx.doi.org/10.1038/s41416-019-0536-0
_version_ 1783475431146520576
author Fernandes, Michael
Rosel, Daniel
Brábek, Jan
author_facet Fernandes, Michael
Rosel, Daniel
Brábek, Jan
author_sort Fernandes, Michael
collection PubMed
description Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced imaging. Past failures are the likely result of equating tumour shrinkage to efficacy, rather than inhibition of tumour spread. In the future, the selection of anti-metastasis drug candidates will probably be based on anti-migratory rather than anti-proliferative potential. Oligometastatic cancer coupled with advanced imaging can serve as a clinical proof-of-concept model.
format Online
Article
Text
id pubmed-6889500
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-68895002020-08-20 Solid cancer: the new tumour spread endpoint opens novel opportunities Fernandes, Michael Rosel, Daniel Brábek, Jan Br J Cancer Editorial Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced imaging. Past failures are the likely result of equating tumour shrinkage to efficacy, rather than inhibition of tumour spread. In the future, the selection of anti-metastasis drug candidates will probably be based on anti-migratory rather than anti-proliferative potential. Oligometastatic cancer coupled with advanced imaging can serve as a clinical proof-of-concept model. Nature Publishing Group UK 2019-08-20 2019-10-01 /pmc/articles/PMC6889500/ /pubmed/31427682 http://dx.doi.org/10.1038/s41416-019-0536-0 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0)
spellingShingle Editorial
Fernandes, Michael
Rosel, Daniel
Brábek, Jan
Solid cancer: the new tumour spread endpoint opens novel opportunities
title Solid cancer: the new tumour spread endpoint opens novel opportunities
title_full Solid cancer: the new tumour spread endpoint opens novel opportunities
title_fullStr Solid cancer: the new tumour spread endpoint opens novel opportunities
title_full_unstemmed Solid cancer: the new tumour spread endpoint opens novel opportunities
title_short Solid cancer: the new tumour spread endpoint opens novel opportunities
title_sort solid cancer: the new tumour spread endpoint opens novel opportunities
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889500/
https://www.ncbi.nlm.nih.gov/pubmed/31427682
http://dx.doi.org/10.1038/s41416-019-0536-0
work_keys_str_mv AT fernandesmichael solidcancerthenewtumourspreadendpointopensnovelopportunities
AT roseldaniel solidcancerthenewtumourspreadendpointopensnovelopportunities
AT brabekjan solidcancerthenewtumourspreadendpointopensnovelopportunities

Ejemplares similares